Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Mar;31(2):152-158.
doi: 10.1111/ajad.13260. Epub 2022 Feb 3.

Are x-waiver trainings enough? Facilitators and barriers to buprenorphine prescribing after x-waiver trainings

Affiliations

Are x-waiver trainings enough? Facilitators and barriers to buprenorphine prescribing after x-waiver trainings

Adam J Gordon et al. Am J Addict. 2022 Mar.

Abstract

Background: In the United States, an x-waiver credential is necessary to prescribe buprenorphine medication treatment for opioid use disorder (B-MOUD). Historically, this process has required certified training, which could be a barrier to obtaining an x-waiver and subsequently prescribing. To address this barrier, the US recently removed the training requirement for some clinicians. We sought to determine if clinicians who attended x-waiver training went on to obtain an x-waiver and prescribe B-MOUD, and to examine what facilitated or impeded B-MOUD prescribing.

Methods: In September 2020, we conducted a cross-sectional, electronic survey of attendees of 15 in-person x-waiver pieces of training from June 2018 to January 2020 within the Veterans Health Administration (VHA). Of the attendees (n = 321), we surveyed current VHA clinicians who recalled taking the training. The survey assessed whether clinicians obtained the x-waiver, had prescribed B-MOUD, and barriers or facilitators that influenced B-MOUD prescribing.

Results: Of 251 eligible participants, 62 (24.7%) responded to the survey, including 27 (43.5%) physicians, 16 (25.8%) advanced practice clinicians, and 12 (19.4%) pharmacists. Of the 43 clinicians who could prescribe, 29 (67.4%) had obtained their x-waiver and 16 (37.2%) had reported prescribing B-MOUD. Prominent barriers to prescribing B-MOUD included a lack of supporting clinical staff and competing demands on time. The primary facilitator to prescribing was leadership support.

Conclusion and scientific significance: Nine months after x-waiver training, two-thirds of clinicians with prescribing credentials had obtained their x-waiver and one-third were prescribing B-MOUD. Removing the x-waiver training may not have the intended policy effect as other barriers to B-MOUD prescribing persist.

PubMed Disclaimer

References

REFERENCES

    1. Volkow N, Benveniste H, McLellan AT. Use and misuse of opioids in chronic pain. Annu Rev Med. 2017;69:451-465. doi:10.1146/annurev-med-011817-044739
    1. Volkow ND, Poznyak V, Saxena S, Gerra G. Network U-WIIS. Drug use disorders: impact of a public health rather than a criminal justice approach. World Psychiatry. 2017;16(2):213-214.
    1. Volkow ND. Personalizing the treatment of substance use disorders. Am J Psychiatry. 2020;177(2):113-116. doi:10.1176/appi.ajp.2019.19121284
    1. Blanco C, Volkow ND. Management of opioid use disorder in the USA: present status and future directions. Lancet. 2019;393(10182):1760-1772. doi:10.1016/s0140-6736(18)33078-2
    1. Volkow ND, Collins FS. The role of science in addressing the opioid crisis. N Engl J Med. 2017;377(4):391-394. doi:10.1056/NEJMsr1706626

Publication types

LinkOut - more resources